How UK healthcare works
The UK spends a smaller share of its GDP on healthcare than most G7 peers, funds nearly all of it from general taxation, and gets life expectancy broadly in line with comparable countries. A short guide to where the money comes from, where it goes, and what it funds.
Dr Seth Rankin
MBChB MRCGP. Founder of LoveMyLife. Former NHS Commissioner and Managing Partner of Wandsworth Medical Centre.
23 April 2026
10 min read
The question "is the NHS good value for money" has a reasonably defensible empirical answer when the numbers are laid out. The United Kingdom spends less of its gross domestic product (GDP) on healthcare than most of its major peers, funds a larger share of that spend from the public purse than almost any comparable country, and achieves health outcomes that sit broadly in the middle of the pack among Organisation for Economic Co-operation and Development (OECD) countries.
This article sets out what the National Health Service (NHS) costs, where the money comes from, what it funds, and how the National Institute for Health and Care Excellence (NICE) decides which treatments enter it. It is intended as background for anyone who wants to understand how the UK system compares on cost and outcomes. Sources are listed at the end.
NHS funding in England comes from three sources.
General taxation is the dominant source. Income tax, Value Added Tax (VAT), and other central taxes fund the Department of Health and Social Care (DHSC) settlement, which is then allocated down to NHS England and the Integrated Care Boards (ICBs) that commission local services.
National Insurance Contributions (NICs) contribute a smaller but significant share.
A small amount of revenue comes from NHS prescription charges, NHS dental charges, paid-for car parking at some hospitals, private work done within NHS facilities, and various overseas visitor charges.
Out-of-pocket costs to the patient are, by international standards, very low. About 81 per cent of total UK healthcare expenditure is publicly financed, against an OECD average of around 60 per cent. Private medical insurance, private self-pay, and patient charges together make up the remaining share, which is smaller in the UK than in most comparable countries.
Total UK healthcare expenditure was 11.1 per cent of GDP in 2024. This figure includes both NHS spending and private healthcare spending.
Among the Group of Seven (G7) advanced economies, the UK sits in the lower half of the distribution.
United States: 17.2 per cent of GDP
Germany: 12.3 per cent
France: 11.5 per cent
United Kingdom: 11.1 per cent
Japan: 10.6 per cent
Italy: 9.0 per cent
Canada sits slightly above the UK. Across the wider OECD, the UK is mid-table: above the OECD average by a small margin, well below the highest spenders, and well above the lowest. The full distribution is published in OECD Health at a Glance 2025.
Per capita, the UK spends less in absolute terms than the US, Germany, and several Nordic countries, and more than some southern European peers. The mix of mid-table percentage spend and relatively high public share means the UK delivers universal coverage at a total cost that is not notably high for a high-income country, and at a patient-side cost that is near zero for most people most of the time.
The NHS funds, from that public settlement, a very broad scope of care:
Primary care through roughly 6,500 general practices across England.
Secondary and tertiary care through around 215 NHS trusts and foundation trusts, including specialist hospitals and teaching hospitals.
Ambulance services, urgent treatment centres, and accident and emergency (A&E) departments.
Community services, district nursing, community mental health teams, and community therapy.
Public health programmes including the national screening programmes, immunisation programmes, and sexual-health services.
The national formulary of prescribed medicines, including very expensive treatments for cancer, rare diseases, and advanced biologics.
High-cost equipment-intensive treatments including transplants, cardiothoracic surgery, neurosurgery, intensive care, and advanced cancer therapies.
Research infrastructure through the National Institute for Health and Care Research (NIHR).
Nothing in that list is rationed by ability to pay. Where rationing occurs, it is by clinical need, by waiting time, and by the availability of a specific service locally.
Health outcomes are the harder half of the value-for-money question. The UK sits broadly in line with peer countries on most headline measures, but the picture is not uniformly positive and has shifted over the last fifteen years.
Life expectancy at birth. UK life expectancy is around 81.9 years, a little below the average for comparable high-income countries of about 82.7 years, per ONS national life tables and OECD Health at a Glance 2025. The UK ranked 19th for male life expectancy and 26th for female life expectancy among the 38 OECD countries in 2022.
Change over time. UK life expectancy gains have slowed more in the UK than in most comparable countries since 2010. The UK was closer to the top of the OECD distribution in 2000 and has drifted toward the middle.
Mortality amenable to healthcare (deaths from conditions that should be avoidable given timely effective care) is broadly at peer level.
Cancer survival. The UK has historically lagged some European peers on five-year survival for common cancers including bowel and lung, while closing the gap on others. Cancer Research UK publishes the full picture.
Infant mortality is slightly above some European peers and below others.
Patient-reported satisfaction with primary care in England has fallen substantially since 2019, per the GP Patient Survey.
Waiting times for non-urgent hospital treatment are a well-documented challenge and have lengthened since 2019.
The honest summary is that the UK delivers outcomes in the peer-country range for most measures, does so at a cost that is toward the lower end for G7 countries, and has real and widely discussed challenges on waiting times, elective access, and the recent slowdown in life-expectancy gains.
NICE sits at the centre of the value-for-money question for new treatments. It is the body that assesses new medicines, medical devices, and procedures before the NHS is required to fund them.
NICE evaluates on two criteria together:
Clinical effectiveness. Does the treatment work, and by how much, for the target patient group? Based on trials, meta-analyses, and real-world evidence.
Cost effectiveness. How much additional health benefit does the treatment deliver per pound spent, measured in Quality-Adjusted Life Years (QALYs)? NICE generally applies a threshold of around £20,000 to £30,000 per QALY for most indications, with flexibility for end-of-life and rare-disease treatments.
A treatment can be highly effective and still not be funded on the NHS if the cost per QALY is very high relative to the benefit. A treatment can be cost effective in principle but still receive a negative appraisal if the evidence base is weak. The process is explicit and published.
A NICE technology appraisal that recommends a treatment triggers a statutory NHS funding duty. NHS commissioners are legally required to fund NICE-approved medicines normally within 90 days of final guidance, and within 30 days for a subset of fast-track appraisals. The duty sits inside the NHS Constitution as a patient right.
The practical consequence is that when NICE approves a new cancer drug, a new biologic, or a new gene therapy, the NHS in England is obliged to make it available to the whole eligible patient population within a defined window. The patient's insurance status, income, or postcode does not determine access. The only gate is clinical eligibility.
In health systems where coverage is driven by private insurance policies or out-of-pocket spending, access to the same new treatments varies by what the patient or their employer has bought, and often by what the insurer will authorise for each case. The NHS mechanism produces a flatter, and typically faster, path to population-level access once a treatment has cleared the NICE process.
There are caveats. NICE rejects or restricts some treatments on cost-effectiveness grounds, and the threshold means not every approved-abroad medicine is approved in the UK. Local ICB formularies can add friction. But the headline pattern holds: approved equals universally available, within a timetable written into law.
A fair view of NHS value for money avoids the two easy overclaims.
It does not mean the NHS is the best-performing health system in the world on every measure. It is not. On waiting times for planned hospital care, the UK sits toward the worse end of the G7 distribution. On five-year cancer survival in several common cancers, the UK lags some European peers. On patient-reported access to primary care appointments, the recent trend has been downwards.
It does not mean the NHS is straightforwardly cheap. Eleven per cent of GDP is a very large sum of money, and the settlement has grown in real terms across most of the last decade. The UK's position is "mid-table", not "bargain".
What the numbers do support is a narrower claim: the UK delivers near-universal access to a comprehensive package of care, including very expensive treatments, on a share of GDP lower than most G7 peers, while keeping patient-side costs close to zero across almost the whole population. That specific combination is rare internationally.
The NHS funds a comprehensive scope of care from general taxation and NICs, at about 11.1 per cent of UK GDP. The public share of UK health expenditure is around 81 per cent, higher than almost all OECD peers. NICE assesses new treatments on clinical and cost effectiveness, and approved technology appraisals trigger a statutory NHS funding duty within 30 to 90 days. Health outcomes are peer-level overall, with real challenges on waiting times, elective access, and the recent slowdown in life-expectancy gains.
The value-for-money claim for the NHS is not "best in the world". It is "universal coverage of a comprehensive package of care, including very expensive treatments, on a mid-table share of GDP". That is what the numbers support, and it is a genuine structural achievement.
Office for National Statistics, Healthcare expenditure, UK Health Accounts 2023 and 2024. UK total and public-financed healthcare spend.
Office for National Statistics, National life tables, UK: 2022 to 2024. Current UK life expectancy figures.
OECD, Health at a Glance 2025: Health expenditure in relation to GDP. OECD comparison of health spend as share of GDP.
OECD, Health at a Glance 2025: Life expectancy at birth. International life-expectancy comparison.
The Health Foundation, Trends in international life expectancy at birth. UK life expectancy change vs comparable high-income countries.
Cancer Research UK, Cancer survival statistics. UK cancer survival in international context.
GP Patient Survey, gp-patient.co.uk. Patient-reported primary-care experience in England.
NICE, About NICE. Organisational remit and structure.
NICE, About technology appraisal guidance. Technology appraisal process and scope.
gov.uk, Introducing new medicines in the NHS in the UK: pathway. Statutory NHS funding requirement and timelines.
NHS Confederation, Are other health systems more cost-effective than the NHS?. NHS value-for-money analysis.
Department of Health and Social Care, dhsc.gov.uk. DHSC budget and NHS settlement.
National Institute for Health and Care Research, nihr.ac.uk. NHS-linked research infrastructure.
Clinically reviewed
Dr Seth Rankin · MBChB MRCGP - Founder and Medical Director, LoveMyLife
Dr Seth Rankin qualified in medicine at Auckland School of Medicine in New Zealand in 1990 and worked as a junior doctor across New Zealand, Australia, and the UK before qualifying as a Member of the Royal College of General Practitioners (MRCGP) through the London Deanery in 2004. He was Managing Partner of Wandsworth Medical Centre from 2006 to 2016 and served as a Board Member of Wandsworth Clinical Commissioning Group for nine years. He is the founder of London Travel Clinic, London Doctors Clinic, London Medical Laboratory, and LoveMyLife.
If you would like a consultation with an MRCGP-registered GP, the next step is to book.
Begin your consultation at this link. Online or in person at Westfield London.